AFP
TEVA icon

Ausdal Financial Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Ausdal Financial Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,490
Closed -$84K – 526
2021
Q4 		$84K Sell
10,490
-2,220
-17% -$20K 0.01% 473
2021
Q3 		$124K Sell
12,710
-4,908
-28% -$46K 0.02% 454
2021
Q2 		$174K Hold
17,618
– – 0.03% 442
2021
Q1 		$203K Sell
17,618
-7,730
-30% -$88.6K 0.03% 414
2020
Q4 		$130K Buy
25,348
+1,950
+8% +$18.7K 0.03% 402
2020
Q3 		$107K Buy
23,398
+11,920
+104% +$126K 0.03% 337
2020
Q2 		$142K Buy
+11,478
New +$130K 0.05% 272
2019
Q4 		– Sell
-15,653
Closed -$108K – 340
2019
Q3 		$108K Buy
15,653
+4,700
+43% +$36K 0.04% 297
2019
Q2 		$87K Sell
10,953
-150
-1% -$1.81K 0.03% 282
2019
Q1 		$174K Sell
11,103
-79
-0.7% -$1.39K 0.07% 257
2018
Q4 		$172K Sell
11,182
-5,550
-33% -$114K 0.08% 228
2018
Q3 		$360K Buy
16,732
+1,090
+7% +$25.3K 0.1% 244
2018
Q2 		$380K Hold
15,642
– – 0.12% 233
2018
Q1 		$267K Buy
+15,642
New +$305K 0.09% 274
2017
Q4 		– Sell
-12,466
Closed -$219K – 370
2017
Q3 		$219K Buy
12,466
+3,141
+34% +$70.7K 0.09% 295
2017
Q2 		$310K Buy
9,325
+2,700
+41% +$83.6K 0.13% 213
2017
Q1 		$213K Buy
+6,625
New +$226K 0.1% 254
2016
Q1 		– Sell
-700
Closed -$46K – 936
2015
Q4 		$46K Buy
+700
New +$43.3K 0.02% 481

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Ausdal Financial Partners's TEVA Position: Q1 2022 in Review

Ausdal Financial Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 10,490 shares — an estimated $84K sold.

Ausdal Financial Partners first reported a position in TEVA in Q4 2015 and held it in 18 quarters. The position peaked at $380K in Q2 2018. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Ausdal Financial Partners reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Ausdal Financial Partners sold 10,490 Teva Pharmaceuticals shares in Q1 2022, an estimated $84K.
  • Ausdal Financial Partners first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 18 quarters.
  • Ausdal Financial Partners's Teva Pharmaceuticals position peaked at $380K in Q2 2018.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Ausdal Financial Partners's 13F filing for Q1 2022, filed 4 May 2022.